The serotonin reuptake transporter (SERT) plays an important role in serotonin neurotransmission and in several psychopathological disorders such as depression and anxiety disorders. In this study, we investigated whether the ovarian steroids, estrogen (E) and progesterone (P) regulate SERT binding, intracellular distribution, and function using [ 3 H]citalopram ligand binding with quantitative autoradiography, immunofluorescence histochemistry with confocal microscopy and [ 3 H]serotonin uptake, respectively. Ovariectomized macaques received either placebo, E alone, P alone or E plus P for 28 days. In the raphe, E, P, and E þ P treatments did not change SERT binding density. In several hypothalamic nuclei, [ 3 H]citalopram binding was increased by E, P, and E þ P. Immunofluorescent SERT in serotonin soma was intracellular and similar among treatments. In the hypothalamus, immunofluorescent SERT was located along the serotonergic axons and there was a significant proliferation of immunofluorescent fibers in hormone-treated animals. In addition, E and E þ P treatment increased serotonin uptake in the basal ganglia. These findings suggest that ovarian hormones regulate SERT protein expression and distribution, perhaps via extracellular serotonin or mRNA stability, but not solely at the level of gene transcription. The serotonin reuptake transporter (SERT) is responsible for the recycle and clearance of serotonin in the brain.
H]citalopram binding was increased by E, P, and E þ P. Immunofluorescent SERT in serotonin soma was intracellular and similar among treatments. In the hypothalamus, immunofluorescent SERT was located along the serotonergic axons and there was a significant proliferation of immunofluorescent fibers in hormone-treated animals. In addition, E and E þ P treatment increased serotonin uptake in the basal ganglia. These findings suggest that ovarian hormones regulate SERT protein expression and distribution, perhaps via extracellular serotonin or mRNA stability, but not solely at the level of gene transcription. The serotonin reuptake transporter (SERT) is responsible for the recycle and clearance of serotonin in the brain. 1 Dysfunction of SERT has been implicated in several affective disorders such as depression and anxiety disorders which exhibit a significantly higher lifetime frequency in women than men. 2, 3 A body of evidence suggests that ovarian hormones can impact mood and cognition. 4, 5 Using a model of surgical menopause and hormone replacement with nonhuman primates, we previously reported that estrogen (E)7progesterone(P) caused a significant reduction in the expression of SERT mRNA in the dorsal raphe nucleus (DRN) 6 and we initially speculated that this reduction in RNA would cause a reduction in reuptake and a prolonged action of synaptic serotonin. However, this line of reasoning was not consistent with clinical studies indicating SERT is reduced in depressed patients 7, 8 and depression is thought to precipitate from decreased serotonergic activity. 2 Thus, information was needed on the regulation of SERT at the protein level in primates.
In all, 20 ovariectomized female rhesus macaques were divided equally among the following treatment groups: control placebo-treated (OVX), E-treated for 28 days, P-treated for 28 days and E þ P-treated (14 days E, then 14 days E þ P). In the first experiment, [ (Figure 1a) . 6 Nonspecific SERT binding defined by the presence of 1 mM fluoxetine was below 15% of the total [ 3 H]citalopram binding. E, P, and E þ P treatments did not change the density of SERT binding sites in the DRN or median raphe nucleus (MRN) compared to the OVX controls (Figure 2a ). Neither the average OD values nor the positive pixel areas from six levels of the DRN and MRN (n ¼ 5/treatment) were different between treatment groups. In the second experiment, immunofluorescence histochemistry for SERT with confocal microscopy was performed. In monkeys treated with ovarian hormones, SERT distribution at the cell body region did not differ from the OVX control animals and it was mainly confined to the cytoplasmic compartment (Figure 3a) . In the hypothalamus, SERT immuno-fluorescence was prominent in all nuclei reported in the binding study. The ST51-2 anti-human SERT antibodies recognized SERT proteins along the surface of serotonin nerve fibers parallel to the plane of sections, such as in the ZI and LTu, as well as the cross-section of fibers perpendicular to the plane of sections, such as in the AH, VMN, and DMH. Fiber staining in the ZI is shown in Figure 3a . In several hypothalamic nuclei, there was an apparent increase in the density of immunofluorescent SERT-expressing fibers. Application of the skeletonization feature of NIH Image software to three levels of the ZI and LTu enabled quantitative assessment of SERT immunofluorescence and the results are shown in Figure 3b . There was a significant increase in the density of immunofluorescent SERT-expressing fibers with hormone replacement in the ZI, but not in the LTu, which correlated with [ The basal ganglia and hippocampi had robust serotonin uptake, whereas the uptake in area 46, cingulate gyrus, occipital lobe of the cortex and the thalamus was below the assay sensitivity.
E and E þ P treatments significantly increased the V max of specific serotonin uptake in the basal ganglia compared to the OVX controls (two-way ANOVA). Serotonin uptake in the hippocampus was not changed by any of the treatments. The K m values were not different among treatment groups in these two serotonergic terminal fields.
Understanding how ovarian hormones impact the function of SERT will provide insight into mood disorders related to reproductive function in women and changes in efficacy of the SSRIs reported for preand post-menopausal women. [9] [10] [11] Together, the citalopram binding and the SERT immunofluorescence indicate an overall increase in the amount of functional SERT protein during hormone replacement with a predominant increase in the amount of SERT trafficked to the axonal fibers and terminal fields. We previously reported that E and E þ P significantly decreased the level of SERT mRNA in the DRN of macaques. 6 The difference between the regulation of SERT mRNA vs protein during E and P replacement suggests that ovarian hormones may increase SERT mRNA or protein stability.
E and P may regulate SERT protein expression and activity by elevating the level of extracellular serotonin. According to one model, 12 when extracellular serotonin is high, SERT will continuously pump serotonin to the inside of cells and the translocation of serotonin prevents SERT phosphorylation and internalization. We found that E7P increased expression of tryptophan hydroxylase 13, 14 and decreased expression of monoamine oxidase A. 15 These actions could increase serotonin synthesis and decrease serotonin degradation, respectively. E7P also decrease 5-HT 1A autoreceptor gene expression, binding activity, and G protein activation which could increase serotonin neuronal firing and serotonin release. 16, 17 Altogether, these actions of E and P likely increase extracellular serotonin which in turn, could prevent SERT internalization and degradation.
Our data also suggest that ovarian hormones may regulate SERT protein sorting and trafficking. Electron microscopy studies indicate that SERT labeling is dense on the plasma membrane along the axons and perisynaptic areas and concentrated in the cytoplasm of the soma and dendrites. 18, 19 The intracellular distribution pattern of SERT at serotonin neuronal soma was not affected by any of the hormone treatment-regimens. However, SERT binding, immunofluorescence, and activity at serotonin nerve terminal regions were increased during hormone replacement. E and P have been found to modify microtubule dynamics 20 and further studies are needed to better understand the factors determining SERT protein sorting and trafficking.
The functional consequence of the proliferation of SERT-expressing fibers is unknown. The possibility that hormone replacement may alter the direction of serotonin transport via SERT bears consideration. SERT has been shown to be in the reverse mode to release serotonin when blocked by psychostimulants such as MDMA and fenfluramine. 21, 22 Other neurotransmitter transporters, including the dopamine transporter, 23, 24 the gamma-aminobutyric acid transporter, 25 and the glycine transporter, 26 may also release their substrates in a cell membrane potential and Na þ ion-dependent fashion. This carrier-based neurotransmitter release differs markedly from synaptical release triggered by Ca 2 þ influx. Thus, it is attractive to speculate that ovarian hormones cause the observed increase in axonal expression of SERT and that membrane potential and ion gradient changes enable SERT to release serotonin along axons. This would widely increase extracellular serotonin in target areas. Along this line of reasoning, the efficacy of SSRIs that block only the uptake but not the release of serotonin via SERT would increase in the presence of ovarian steroids.
In this study, we observed an increase of [ 3 H]serotonin uptake with hormone replacement in the monkey caudate (basal ganglia), but not hippocampus. The region-specific regulation of SERT may be because of the origin of the serotonin innervation. We previously reported that E7P treatment alters SERT mRNA in the DRN, but not the MRN 6 and serotonin innervation of the caudate originates mainly from the DRN, whereas the serotonin innervation of the hippocampus is largely from the MRN. 27 In depressed patients, SERT binding is decreased in the caudate but not in the hippocampus. 7, 8 We observed that P alone increased SERT binding and SERT immunofluorescence, but not [ 3 H]serotonin uptake in the basal ganglia. Although protein synthesis is dependent upon an action of P in serotonin cell bodies of the DRN, there may be further modifications of SERT activity in each terminal field that are membrane dependent. Thus, a difference between SERT protein availability and functional activity may occur.
In conclusion, hormone replacement in nonhuman primates did not change SERT binding sites and intracellular distribution in the raphe, but it markedly increased the density of SERT binding, immunofluorescence, and serotonin uptake in selected serotonergic terminal fields without affecting the affinity of the transporter. Closer examination of the role of ovarian hormones in SERT trafficking and directionality of the serotonin transport via SERT are indicated. 
Methods

Reagents
Animals and treatments
This study was approved by the Institutional Animal Care and Use Committee of the Oregon National Illustration of specific serotonin uptake in the basal ganglia of OVX-, E-, P-, and E þ P-treated macaques. A model for one-site uptake best described the saturable transport of serotonin. Specific serotonin uptake saturated at 150-350 nM serotonin in all treatment groups. (c) K m and V max values from the basal ganglia and hippocampus. Serotonin uptake was significantly increased in the basal ganglia (P ¼ 0.007, F ¼ 6.046, df ¼ 17), but not in the hippocampus, in E-and E þ P-treated macaques. *Significantly different from the OVX control group.
Primate Research Center (ONPRC). Twenty adult female rhesus monkeys (Macaca mulatta) were acquired, ovariectomized, treated and euthanized according to procedures recommended by the Panel on Euthanasia of the American Veterinary Association. Surgery, steroid hormone treatment, euthanasia, brain perfusion, tissue harvest, cryosectioning and mounting of brain sections were described in detail previously. 17 [ 3 H]Citalopram binding SERT binding experiments were performed on representative hypothalamic and midbrain sections according to Duncan et al 28 with minor modifications. Briefly, slides were brought to room temperature in vacuum and pre-incubated with assay buffer (50 mM Tris, 120 mM NaCl, and 5 mM KCl, pH 7.4) at 221C for 15 min. Slides were then incubated with 2 nM [3H]citalopram in the assay buffer at 221C for 1 h. Non-specific binding was defined with the presence of 1 mM fluoxetine on adjacent sections. Citalopram, mazindol, GBR-12935 at 0.1 and 1 mM were also added in some experiments to evaluate the selectivity of the assay. Fluoxetine and citalopram are selective serotonin reuptake inhibitors (SSRIs) and have high affinity for SERT. In contrast, mazindol has high affinity for norepinepherine transporter whereas GBR-12935 has high affinity for dopamine transporters. 29 The sections were washed and dried rapidly under a stream of cold air.
Matching sections from OVX controls, E-, P-and (E þ P)-treated monkeys were processed in the same experiment and exposed to 3 H-sensitive hyperfilms along with 3 H autoradiographic micro-scales (Amersham, Arlington Heights, IL, USA) for 3-5 weeks. Autoradiograms were digitized with a SONY CCD video camera. Densitometry was performed using NIH image on a Macintosh computer. Each film was calibrated with 3 H autoradiographic microscales.
Densitometry
NIH image was used to analyze the autoradiograms. Details of the computer-assisted image analysis have been published previously. 17 The operator outlines the area for analysis and the total area is held constant for each nucleus. The parameters obtained are the optical density of the signal and positive pixel area which are then subjected to statistical analysis. Areas examined were the DRN, MRN, and hypothalamic nuclei including the anterior hypothalamus (AH), periventricular nuclei (PeV), lateral hypothalamus (LH), lateral tuberal nuclei (LTu), ventromedial nucleus (VMN), dorsomedial hypothalamus (DMH), zona incerta (ZI), and mammillary bodies (MAM).
Immunofluorescent labeling of SERT and confocal microscopy Monkey midbrain and hypothalamic sections were fixated in 4% paraformaldehyde for 10 min at 41C.
After several washes and incubation with normal goat serum, tissue sections were incubated in the antihuman SERT antibody (ST51-2, 1 : 500) overnight at 41C. After further washes and another incubation with normal goat serum, the sections were incubated with goat anti-mouse antibodies conjugated with Alexa 488 (1 : 100) for an hour. Then, the sections were incubated with bis-benzimine (Hoechst 33258, Molecular Probes, Inc.) to label the nuclei for structural references followed by incubation with 10 mM CuSO 4 in 50 mM ammonium acetate buffer (pH 5.0) for 45 min to reduce lipofucscin-like autofluorescence. Sections were then mounted with buffered glycerol and coverslipped. The intracellular distribution of immunolabeled SERT was examined with a Leica TCS SP confocal system (Heidelberg, Germany). Alexa 488 was imaged using the 488 nm excitation line of an argon laser and an emission band pass filter of 530730 nm. Bis-benzimine was excited with the 364 nm Argon UV laser and imaged through a 440740 nm band pass filter. A 40 Â NA 1.25 PlanApochromat objective was used for all images. In all treatment groups, z-sections of immunofluorescent SERT signals were imaged throughout the thickness of the section at a 0.5 mm interval. The confocal images were presented as maximum value projection images of a series of optical planes covering the entire10 mm thickness of each section with the assistance of MetaMorph software (Universal Imaging, West Chester, PA, USA).
Two areas of the hypothalamus containing immunofluorescence fibers parallel to the plane of section, the ZI and LTu, were chosen for quantitative analysis using the skeletonization feature of NIH Image. The positive pixel areas were divided by the size of the fluorescent image to yield the density of the fiber. Three sections containing each nucleus from each animal in the four treatment groups were analyzed. The numbers of SERT-positive fibers in three representative fields per section generated the average value for each animal. The remaining frontal cortices, temporal, and parietal lobes from the same animals were thawed in 0.32 M. sucrose at room temperature and microdissected to obtain area 46, cingulate, striata, and hippocampi. The tissues were weighed and homogenized in 10 volumes of 0.32 M sucrose at 41C by hand with 15 strokes of a glass-Teflon homogenizer. The homogenate was centrifuged at 1000 g for 10 min at 41C, and the supernatant was further centrifuged at 20 000 g for 20 min at 41C. The resulting pellet was resuspended in seven volumes (original wet weight of tissue) of 0.32 M glucose at 41C. Synaptosomal preparations (50 ml, 100-200 mg protein) were preincubated in Krebs-HEPES buffer (25 mM HEPES, 122 mM NaCl, 2.5 mM CaCl 2 , 1.2 mM MgSO 4 , pH 7.4) supplemented with 10 mM pargyline, 100 mM tropolone, 30 nM methiothepin, 0.2% glucose, and 0.02% ascorbic acid in 1-ml assay tubes (Marsh Biomedical, Rochester, NY, USA) at 301C for 10 min. [ 3 H]Serotonin uptake was initiated by the addition of serotonin at eight concentrations ranging from 10 to 810 nM and terminated after 10 min by filtration through Wallac A filters presoaked in 0.05% polyethylenimine using a Tomtec 96-well cell harvester. Serotonin at each concentration contained 10 nM of [ 3 H]serotonin and 0-800 nM of unlabeled serotonin. Specific uptake was defined as the difference in uptake observed in the absence and presence of 5 mM fluoxetine. The final assay volume in each tube was 500 ml. Filters were washed for 6 s with saline and air-dried. Scintillation fluid (b-Scint) was added to each filtered spot and radioactivity remaining on the filters was determined using a Wallac b-plate reader. Each experiment was conducted with triplicate determinations. Protein was determined with a modified method of Lowry et al. 30 In addition, selectivity of [ 3 H]serotonin (10 nM) uptake by monkey striatal synaptosomes was determined in the presence of citalopram, fluoxetine, mazindol, and GBR-12935 at concentrations ranging from 0.1 nM to 10 mM.
Hormone assays
Serum concentrations of estrogen, progesterone and prolactin at the time of necropsy were reported previously. 17 
Statistics
The average densitometric values and steroid hormone concentrations from each treatment group were compared with one-way analysis of variance (ANO-VA) followed by Student-Newman-Keuls post hoc pairwise comparisons. Saturation and competition curves from uptake assays were analyzed with a nonlinear regression curve fitting program. The maximal transport (V max ) and Michaelis-Menton constant (K m ) of serotonin uptake among treatments and brain regions were compared with two-way ANOVA. When a difference among treatment groups was indicated by the two-way ANOVA, one-way ANOVA and post hoc pairwise comparisons were performed to further determine the differences between treatments at each brain area. All analyses and statistical comparisons between treatments were conducted with Prism 3.0 (San Diego, CA, USA). A confidence level of Po0.05 was considered significant.
